Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity [0.03%]
针对SMARCB1基因缺失的肾髓质癌表皮生长因子受体信号通路阻断的药理学研究及临床活性评估:基于帕尼单抗药物的研究基础与临床应用前景
Niki M Zacharias,Eric S Rupe,Xinyue Chen et al.
Niki M Zacharias et al.
Purpose: SMARCB1-deficient renal medullary carcinoma (RMC) is an ultrarare, lethal malignancy refractory to therapies approved for other renal cell carcinomas, and its rarity makes randomized trials logistically unfeasibl...
Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer [0.03%]
超灵敏循环肿瘤DNA分析可提高局部晚期食管癌分子残留病灶检测的准确性
Justin Rhoades,Anuj Patel,Kan Xiong et al.
Justin Rhoades et al.
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment...
Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial [0.03%]
Danvatirsen联合帕博利珠单抗对比帕博利珠单抗治疗复发性和/或转移性头颈鳞癌(PEMDA-HN)的随机II期试验
Nabil F Saba,Marshall Posner,Kevin Harrington et al.
Nabil F Saba et al.
Purpose: STAT3 is important in promoting a pro-oncogenic tumor microenvironment. This first randomized trial of a STAT3-targeting ASO with pembrolizumab assessed whether this first-line combination would improve outcomes ...
Efficacy of actinium-225-labeled fully human anti-MUC-16 radioimmunoconjugate against MUC-16-positive ovarian and pancreatic ductal adenocarcinoma xenograft models [0.03%]
用于治疗卵巢癌和胰腺导管腺癌的小鼠模型的锕-225放射免疫结合物的疗效研究
Hanan Babeker,Emmanuel Nwangele,Alissar Monzer et al.
Hanan Babeker et al.
Purpose: MUC-16-targeted antibodies can deliver contrast agents (diagnostic) and/or cytotoxic payloads (therapy) to the tumor site. MUC-16 is overexpressed in 80% of epithelial ovarian cancer (EOC) and 65% of pancreatic d...
Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study [0.03%]
MEDI1191(IL-12信使RNA脂质体纳米颗粒)瘤内注射联合静脉注射durvalumab治疗晚期实体瘤患者的安全性及疗效:一项首次人体试验
Benedito A Carneiro,Thomas Marron,Dmitriy Zamarin et al.
Benedito A Carneiro et al.
Purpose: MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, p...
Proteogenomic profiling identifies FGFR2b as a prevalent cell-surface target in intrahepatic cholangiocarcinoma [0.03%]
蛋白质组学谱分析鉴定FGFR2b为肝内胆管癌中常见的细胞表面靶点
Nakul M Shah,Beatriz Alvarado-Hernandez,Xinyue Chen et al.
Nakul M Shah et al.
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody-...
Longitudinal Phenotyping of Circulating Tumor Cells using a Scalable Deep Learning Framework [0.03%]
一种可扩展的深度学习框架对循环肿瘤细胞纵向表型分型的研究
Matthew L Bootsma,Marina N Sharifi,Jamie M Sperger et al.
Matthew L Bootsma et al.
Purpose: Circulating tumor cells (CTCs) provide a minimally invasive window into metastatic disease and treatment response, but their clinical utility has been constrained by manual, subjective, low-throughput identificat...
Whole Genome HPV Liquid Biopsy for HPV-Associated Cancer Detection and Viral Physical State Classification [0.03%]
用于HPV相关癌症检测及病毒物理状态分类的全基因组HPV液体活检技术
Adam S Fisch,Annie R Abruzzo,Samuli Eldfors et al.
Adam S Fisch et al.
Purpose: HPV-associated carcinomas(HPV+cancers) account for 5% of all cancers. Circulating tumor HPV DNA(ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. While...
Baseline circulating and tumor γδ T cells and early circulating CD8⁺PD1⁺ expansion predict response to Atezolizumab-bevacizumab in HCC [0.03%]
基线循环和肿瘤γδT细胞及早期循环CD8⁺PD1⁺扩张预测了atezolizumab-bevacizumab在肝癌治疗中的反应
Isabelle Galy-Fauroux,Amna Asif-Laidin,Manon Evain et al.
Isabelle Galy-Fauroux et al.
Background: We aimed to identify circulating and tumor immune features predictive of oncological outcomes under Atezolizumab-Bevacizumab (AtezoBev) therapy for hepatocellular carcinoma (HCC). ...
Adel Shahnam,Mrinal M Gounder
Adel Shahnam
Although BRIGHTLINE-1 was headlined as a "negative trial," brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed contro...